Compare VCEL & FTF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VCEL | FTF |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 250.9M |
| IPO Year | 1997 | N/A |
| Metric | VCEL | FTF |
|---|---|---|
| Price | $35.89 | $6.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $57.50 | N/A |
| AVG Volume (30 Days) | ★ 425.1K | 153.9K |
| Earning Date | 02-26-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.45% |
| EPS Growth | ★ 236.54 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $258,716,999.00 | N/A |
| Revenue This Year | $18.02 | N/A |
| Revenue Next Year | $18.52 | N/A |
| P/E Ratio | $137.75 | ★ N/A |
| Revenue Growth | ★ 14.05 | N/A |
| 52 Week Low | $29.24 | $5.76 |
| 52 Week High | $58.77 | $6.56 |
| Indicator | VCEL | FTF |
|---|---|---|
| Relative Strength Index (RSI) | 42.11 | 51.00 |
| Support Level | $33.30 | $6.19 |
| Resistance Level | $36.56 | $6.29 |
| Average True Range (ATR) | 1.56 | 0.03 |
| MACD | -0.27 | -0.00 |
| Stochastic Oscillator | 28.50 | 61.11 |
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.